

- GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lung Cancer [database on the Internet]. International Agency for Research on Cancer, World Health Organization. 2013 [cited January 8, 2014]. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Tong L, Spitz MR, Fueger JJ, et al. Lung carcinoma in former smokers. *Cancer* 1996;78:1004–1010.
- Garces YI, Yang P, Parkinson J, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. *Chest* 2004;126:1733–1741.
- Visbal AL, Williams BA, Nichols FC 3rd, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. *Ann Thorac Surg* 2004;78:209–215, discussion 215.
- Adler I. *Primary Malignant Growth of the Lung and Bronchi*. New York, NY: Longman, Green Company; 1912.
- Ochsner A, DeBakey M. Carcinoma of the lung. *Arch Surg* 1941;42:209–258.
- Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. *Br Med J* 1950;2:739–748.
- Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. *JAMA* 1950;143:329–336.
- Smoking and Health: Summary of a Report of the Royal College of Physicians of London on Smoking in Relation to Cancer of the Lung and Other Diseases*. London, UK: Pitman Medical Publishing; 1962.
- US Public Health Service. *Smoking and Health. Report of the Advisory Committee to the Surgeon General for the Public Health Service*. Publication No. 1103. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service; 1964.
- Burns DM, Anderson CM, Gray N. Has the lung cancer risk from smoking increased over the last fifty years? *Cancer Causes Control* 2011;22:389–397.
- Rodgman A, Smith CJ, Perfetti TA. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. *Hum Exp Toxicol* 2000;19:573–595.
- Smith CJ, Perfetti TA, Mullens MA, et al. “IARC group 2B Carcinogens” reported in cigarette mainstream smoke. *Food Chem Toxicol* 2000;38:825–848.
- Smith CJ, Perfetti TA, Rumpel MA, et al. “IARC group 2A Carcinogens” reported in cigarette mainstream smoke. *Food Chem Toxicol* 2000;38:371–383.
- Hoffmann D, Djordjevic MV, Rivenson A, et al. A study of tobacco carcinogenesis. II. Relative potencies of tobacco-specific N-nitrosamines as inducers of lung tumours in A/J mice. *Cancer Lett* 1993;71:25–30.
- Belinsky SA, Devereux TR, Maronpot RR, et al. Relationship between the formation of promutagenic adducts and the activation of the K-ras proto-oncogene in lung tumors from A/J mice treated with nitrosamines. *Cancer Res* 1989;49:5305–5311.
- Eccles R. Menthol and related cooling compounds. *J Pharm Pharmacol* 1994;46:618–630.
- Brooks DR, Palmer JR, Strom BL, et al. Menthol cigarettes and risk of lung cancer. *Am J Epidemiol* 2003;158:609–616, discussion 617–620.
- Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. *BMJ* 2000;321:323–329.
- Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. *Clin Cancer Res* 2009;15:2626–2645.
- Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. *Nat Rev Cancer* 2007;7:778–790.
- Takemiya M, Shiraishi S, Teramoto T, et al. Bloom’s syndrome with porokeratosis of Mibelli and multiple cancers of the skin, lung and colon. *Clin Genet* 1987;31:35–44.
- Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. *Am J Hum Genet* 2004;75:460–474.
- Spitz MR, Wei Q, Dong Q, et al. Genetic susceptibility to lung cancer: the role of DNA damage and repair. *Cancer Epidemiol Biomarkers Prev* 2003;12:689–698.
- Zhou W, Liu G, Thurston SW, et al. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. *Cancer Epidemiol Biomarkers Prev* 2002;11:15–21.
- Ye Z, Song H, Higgins JP, et al. Five glutathione S-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. *PLoS Med* 2006;3(4):e91.
- Lissowska J, Foretova L, Dabek J, et al. Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. *Cancer Causes Control* 2010;21:1091–1104.
- Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. *Br J Cancer* 2008;98:270–276.
- De Matteis S, Consonni D, Bertazzi PA. Exposure to occupational carcinogens and lung cancer risk. Evolution of epidemiological estimates of attributable fraction. *Acta Biomed* 2008;79:34–42.
- Doll R. Mortality from lung cancer in asbestos workers. *Br J Ind Med* 1955;12:81–86.
- Markowitz SB, Levin SM, Miller A, et al. Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. *Am J Respir Crit Care Med* 2013;188:90–96.
- Lubin JH, Boice JD Jr, Edling C, et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. *J Natl Cancer Inst* 1995;87:817–827.
- Krewski D, Lubin JH, Zielinski JM, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. *Epidemiology* 2005;16:137–145.
- Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ* 2005;330:223.
- US Environmental Protection Agency. *Technical Support Document for the 1992 Citizen’s Guide to Radon*. Washington, DC: US Environmental Protection Agency; 1992.
- Shimizu Y, Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). *Radiat Res* 1990;121:120–141.
- Darby SC, Doll R, Gill SK, et al. Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. *Br J Cancer* 1987;55:179–190.
- Davis FC, Boice JD Jr, Hrubec Z, et al. Cancer mortality in a radiation-exposed cohort of Massachusetts tuberculosis patients. *Cancer Res* 1989;49:6130–6136.
- Epstein DM, Geffer WB, Miller WT. Lobar bronchioloalveolar cell carcinoma. *Am J Radiol* 1982;139:463–466.
- Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. *J Natl Cancer Inst* 2004;96:826–834.
- Gallicchio L, Boyd K, Matanoski G, et al. Carotenoids and the risk of developing lung cancer: a systematic review. *Am J Clin Nutr* 2008;88:372–383.
- Lam TK, Gallicchio L, Lindsley K, et al. Cruciferous vegetable consumption and lung cancer risk: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2009;18:184–195.
- Tardon A, Lee WJ, Delgado-Rodriguez M, et al. Leisure-time physical activity and lung cancer: a meta-analysis. *Cancer Causes Control* 2005;16:389–397.
- Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. *Arch Intern Med* 2003;163:1475–1480.
- Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. *Am J Respir Crit Care Med* 2007;176:285–290.
- Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. *J Clin Oncol* 2006;24:5216–5222.
- Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. *Am J Physiol Lung Cell Mol Physiol* 2006;291:L46–L57.
- Yang P, Sun Z, Krowka MJ, et al. Alpha-1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. *Arch Intern Med* 2008;168:1097–1103.
- Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. *Am J Respir Crit Care Med* 2000;161:5–8.
- Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. *Respir Med* 2007;101:2534–2540.
- Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2:706–714.
- Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2007;2:593–602.
- Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. *J Thorac Oncol* 2007;2:603–612.
- Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. *J Thorac Oncol* 2007;2:686–693.
- Goldstraw P, Crowley J. The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. *J Thorac Oncol* 2006;1:281–286.
- Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *J Thorac Oncol* 2007;2:1067–1077.

58. Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2008;3:1213–1223.
59. Detterbeck F, Tanoue L, Boffa DJ. The new lung cancer staging system. *Chest* 2009;136:260–271.
60. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol* 2006;24:4539–4544.
61. Detterbeck FC. Maintaining aim at a moving target. *J Thor Oncol* 2011;6:417–422.
62. Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. *Sci Transl Med* 2013;5:209ra153.
63. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244–285.
64. Travis WD, Brambilla E, Muller-Hermlink HD, et al., eds. *Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart*. Lyon, France: IARC Press; 2004.
65. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–674.
66. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70.
67. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012;150:1107–1120.
68. Detterbeck FC. Stage classification and prognosis: an intersection of medicine, quantum physics and religion? *Thorax* 2011;66:1016–1017.
69. Detterbeck FC. Stage classification and prediction of prognosis: difference between accountants and speculators. *J Thor Oncol* 2013;8:820–822.
70. Chansky K, Sculier J, Crowley J, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol* 2009;4:792–801.
71. Brennan P, Crispo A, Zaridze D, et al. High cumulative risk of lung cancer death among smokers and nonsmokers in Central and Eastern Europe. *Am J Epidemiol* 2006;164:1233–1241.
72. World Health Organization. *WHO Framework Convention on Tobacco Control*. Geneva, Switzerland: World Health Organization; 2007.
73. Hammond D, Fong CT, Borland R, et al. Text and graphic warnings on cigarette packages: findings from the international tobacco control four country study. *Am J Prev Med* 2007;32:202–209.
74. Wright AA, Katz IT. Tobacco tightrope—balancing disease prevention and economic development in China. *N Engl J Med* 2007;356:1493–1496.
75. Public Law 111-31 June 22, 2009. Family Smoking Prevention and Tobacco Control Act.
76. Leone F, Evers-Casey S, Toll B, et al. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e61S–e77S.
77. Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. *J Thorac Cardiovasc Surg* 2007;133:1193–1200.
78. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. *J Natl Cancer Inst* 1997;89:1782–1788.
79. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. *J Natl Cancer Inst* 1998;90:1335–1345.
80. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150–1155.
81. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. *N Engl J Med* 1994;330:1029–1035.
82. Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. *JAMA* 2003;290:476–485.
83. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145–1149.
84. Szabo E, Mao JT, Lam S, et al. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e40S–e60S.
85. Marcus PM, Bergstralh EJ, Zweig MH, et al. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. *J Natl Cancer Inst* 2006;98:748–756.
86. Doria-Rose VP, Marcus PM, Szabo E, et al. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. *Cancer* 2009;115:5007–5017.
87. Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. *Chest* 1984;86:44–53.
88. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. *Cancer* 1991;67:1155–1164.
89. Kubik A, Parkin DM, Khat M, et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. *Int J Cancer* 1990;45:26–33.
90. Manser RL, Irving LB, Stone C, et al. Screening for lung cancer. *Cochrane Database Syst Rev* 2004;(1):CD001991.
91. Oken MM, Hocking WC, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. *JAMA* 2011;306:1865–1873.
92. Aberle D, Adams A, Berg C, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
93. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography. *Am J Respir Crit Care Med* 2009;180:445–453.
94. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax* 2012;67:296–301.
95. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev* 2012;21:308–315.
96. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA* 2012;307:2418–2429.
97. Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e78S–e92S.
98. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg* 2012;144:33–38.
99. Rocco G, Allen M, Altorki N, et al. Clinical statement on the role of the surgeon and surgical issues relating to CT screening programs for lung cancer: Report from The Society of Thoracic Surgeons CT Screening for Lung Cancer Task Force. *Ann Thorac Surg* 2013;96:357–360.
100. Wood D, Eapen G, Ettinger D, et al. Lung cancer screening. *J Natl Compr Canc Netw* 2011;10:240–265.
101. Moyer V, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160:330–338.
102. de Koning H, Meza R, Plevritis S, et al. *Benefits and Harms of Computed Tomography Lung Cancer Screening Programs for High-Risk Populations*. AHRQ Publication No. 13-05196-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
103. Detterbeck F, Gibson C. Turning gray: the natural history of lung cancer over time. *J Thorac Oncol* 2008;3:781–792.
104. Detterbeck FC. Cancer, concepts, cohorts and complexity: avoiding oversimplification of overdiagnosis. *Thorax* 2012;67:842–845.
105. Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. *Ann Intern Med* 2012;157:571–573.
106. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. *N Engl J Med* 2013;368:728–736.
107. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. *J Natl Cancer Inst* 2007;99:715–726.
108. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. *J Natl Cancer Inst* 2003;95:470–478.
109. Ost D, Yeung S, Tanoue L, et al. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e121S.
110. Silvestri GA, Gonzalez AV, Jantz M, et al. Methods of staging for non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e211S–e250S.
111. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules: application to small radiologically indeterminate nodules. *Arch Intern Med* 1997;157:849–855.
112. Swensen SJ, Silverstein MD, Edell ES, et al. Solitary pulmonary nodules: Clinical prediction model versus physicians. *Mayo Clin Proc* 1999;74:319–329.
113. Cummings S, Lillington G, Richard R. Estimating the probability of malignancy in solitary pulmonary nodules: a Bayesian approach. *Am Rev Respir Dis* 1986;134:449–452.
114. Tammemagi C, Pinsky P, Caporaso N, et al. Lung cancer risk prediction: prostate, colorectal and ovarian cancer screening trial models and validation. *J Natl Cancer Inst* 2011;103:1058–1068.
115. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med* 2013;369:910–919.

116. Rivera M, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e142S–e165S.
117. Ost DE, Niu J, S Elting L, et al. Quality gaps and comparative effectiveness in lung cancer staging and diagnosis. *Chest* 2014;145:331–345.
118. Detterbeck F, Khandani AH. The role of PET imaging in solitary pulmonary nodules. *Clin Pulm Med* 2009;16:81–88.
119. Gould MK, Donington J, Lynch W, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? *Chest* 2013;143:e93S–e120S.
120. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. *Clin Cancer Res* 2000;6:3837–3844.
121. Rolston KV, Rodriguez S, Dholakia N, et al. Pulmonary infections mimicking cancer: a retrospective, three-year review. *Support Care Cancer* 1997;5:90–93.
122. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. *Am J Respir Crit Care Med* 1995;152:225–230.
123. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494–500.
124. Reed C, Harpole D, Posther K, et al. Results of the American College of Surgeons Oncology Group 20050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2003;126:1943–1951.
125. Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest, and abdomen in the postoperative assessment of non-small cell lung cancer. *Thorax* 1988;43:883–886.
126. Ichinose Y, Hara N, Ohta M, et al. Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages I and 2 non-small cell lung cancer: preoperative examination for lung cancer. *Chest* 1989;96:1104–1109.
127. Salvatierra A, Baamonde C, Llamas JM, et al. Extrathoracic staging of bronchogenic carcinoma. *Chest* 1990;97:1052–1058.
128. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. *Int J Radiation Oncology Biol Phys* 2001;50:287–293.
129. Sazon DA, Santiago SM, Hoo GW, et al. Fluorodeoxyglucose—positron emission tomography in the detection and staging of lung cancer. *Am J Respir Crit Care Med* 1996;153:417–421.
130. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. *Ann Thorac Surg* 1998;66:886–893.
131. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. *J Clin Oncol* 2004;22:2357–2362.
132. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. *Radiology* 2000;215:886–890.
133. Eschmann SM, Friedel C, Paulsen F, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. *Eur J Nucl Med Mol Imaging* 2002;29:804–808.
134. Michel F, Soler M, Imhof E, et al. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. *Thorax* 1991;40:409–413.
135. Modini C, Passariello R, Iacone C, et al. TNM staging in lung cancer: role of computed tomography. *J Thorac Cardiovasc Surg* 1982;84:569–574.
136. Quinn DL, Ostrow LB, Porter DK, et al. Staging of non-small cell bronchogenic carcinoma: relationship of the clinical evaluation to organ scans. *Chest* 1986;89:270–275.
137. Maziak DE, Darling CE, Inculter RI, et al. Positron emission tomography in staging early lung cancer. *Ann Intern Med* 2009;151:221–228.
138. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. *N Engl J Med* 2009;361:32–39.
139. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. *Lancet* 2002;359:1388–1392.
140. Herder CJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. *J Clin Oncol* 2006;24:1800–1806.
141. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version 2.2014.
142. Detterbeck F, Puchalski J, Rubinowitz A, et al. Classification of the thoroughness of mediastinal staging of lung cancer. *Chest* 2010;137:436–442.
143. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer. *JAMA* 2010;304:2245–2252.
144. Detterbeck FC, Lewis S, Diekemper R, et al. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:7S–37S.
145. Little AG, Gay EC, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. *Lung Cancer* 2007;57:253–260.
146. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? *Chest* 2000;117:1239–1246.
147. Potosky AL, Saxman S, Wallace RB, et al. Population variations in the initial treatment of non-small-cell lung cancer. *J Clin Oncol* 2004;22:3261–3268.
148. Farjah F, Flum D, Ramsey S, et al. Multi-modality mediastinal staging for lung cancer among Medicare beneficiaries. *J Thorac Oncol* 2009;4:355–363.
149. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. *Ann Thorac Surg* 2005;80:2051–2056.
150. Vest M, Tanoue L, Soulos P, et al. Thoroughness of mediastinal staging in stage IIIA non-small cell lung cancer. *J Thor Oncol* 2012;7:188–195.
151. Howington J, Blum M, Chang A, et al. Treatment of stage I and II non-small cell lung cancer. *Chest* 2013;43:e278S–e313S.
152. von Meyenfeldt E, Gooiker G, van Gijn W, et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. *J Thorac Oncol* 2012;7:1170–1178.
153. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. *J Clin Oncol* 2000;18:2327–2340.
154. Hafera AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. *N Engl J Med* 2009;361:1368–1375.
155. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008;26:3552–3559.
156. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542–2550.
157. Groom PA, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol* 2007;2:694–705.
158. Detterbeck FC, Postmus PE, Tanoue L. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e191S–e210S.
159. Cheng D, Downey RJ, Kernstine K, et al. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. *Innovations* 2007;2:261–292.
160. Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. *J Clin Oncol* 2009;27:2553–2562.
161. Chen FF, Zhang D, Wang YL, et al. Video-assisted thoracoscopic surgery lobectomy versus open lobectomy in patients with clinical stage non-small cell lung cancer: a meta-analysis. *Eur J Surg Oncol* 2013;39:957–963.
162. Zhang Z, Zhang Y, Feng H, et al. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2013;44:407–414.
163. Taioli E, Lee DS, Lesser M, et al. Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis. *Eur J Cardiothorac Surg* 2013;44:591–597.
164. Cai Y, Fu X, Xu Q, et al. Thoracoscopic lobectomy versus open lobectomy in Stage I non-small cell lung cancer: a meta-analysis. *PLoS One* 2013;8:e82366.
165. Li Z, Liu H, Li L. Video-assisted thoracoscopic surgery versus open lobectomy for stage I lung cancer: A meta-analysis of long-term outcomes. *Exp Ther Med* 2012;3:886–892.
166. Ceppa D, Kosinski A, Berry M, et al. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons database analysis. *Ann Surg* 2012;256:487–493.
167. Farjah F, Wood DE, Mulligan MS, et al. Safety and efficacy of video-assisted versus conventional lung resection for lung cancer. *J Thorac Cardiovasc Surg* 2009;137:1415–1421.
168. Park H, Detterbeck F, Boffa D, et al. Impact of hospital volume of thoracoscopic lobectomy on primary lung cancer outcomes. *Ann Thorac Surg* 2012;93:372–379.
169. Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multi-institutional database analysis. *Ann Thorac Surg* 2012;93:1027–1032.
170. Licht PB, Jørgensen OD, Ladegaard L, et al. A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. *Ann Thorac Surg* 2013;96:943–950.
171. Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. *J Thorac Cardiovasc Surg* 2010;139:366–378.
172. Paul S, Sedrakyan A, Chiu YL, et al. Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database. *Eur J Cardiothorac Surg* 2013;43:813–817.
173. Cao C, Manganas C, Ang SC, et al. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. *Interact CardioVasc Thorac Surg* 2013;16:244–249.
174. Cao C, Zhu ZH, Yan TD, et al. Video-assisted thoracic surgery versus open thoracotomy for non-small-cell lung cancer: a propensity score analysis based on a multi-institutional registry. *Eur J Cardiothorac Surg* 2013;44:849–854.

175. Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. *J Thorac Cardiovasc Surg* 2014;147:747–753.
176. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J Thorac Cardiovasc Surg* 2010;139:976–983.
177. Flores RM, Park BJ, Dycoco J, et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. *J Thorac Cardiovasc Surg* 2009;138:11–18.
178. Villamizar NR, Darrabie MD, Burfeind WR, et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. *J Thorac Cardiovasc Surg* 2009;138:419–425.
179. Lee PC, Nasar A, Port JL, et al. Long-term survival after lobectomy for non-small cell lung cancer by video-assisted thoracic surgery versus thoracotomy. *Ann Thorac Surg* 2013;96:951–961.
180. Ilonen IK, Räsänen JV, Knuutila A, et al. Anatomic thoracoscopic lung resection for non-small cell lung cancer in stage I is associated with less morbidity and shorter hospitalization than thoracotomy. *Acta Oncol* 2011;50:1126–1132.
181. Jeon JH, Kang CH, Kim HS, et al. Video-assisted thoracoscopic lobectomy in non-small-cell lung cancer patients with chronic obstructive pulmonary disease is associated with lower pulmonary complications than open lobectomy: a propensity score-matched analysis. *Eur J Cardiothorac Surg* 2014;45:640–645.
182. Scott W, Matteotti R, Egleston B, et al. A comparison of perioperative outcomes of Video-Assisted Thoracic Surgical (VATS) Lobectomy with open thoracotomy and lobectomy: results of an analysis using propensity score based weighting. *Ann Surg Innov Res* 2010;4:1.
183. Kirby TJ, Mack MJ, Landreneau RJ, et al. Lobectomy—video-assisted thoracic surgery versus muscle-sparing thoracotomy: a randomized trial. *J Thorac Cardiovasc Surg* 1995;109:997–1002.
184. Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. *World J Surg* 2000;24:27–31.
185. Craig SR, Leaver HA, Yap PL, et al. Acute phase responses following minimal access and conventional thoracic surgery. *Eur J Cardiothorac Surg* 2001;20:455–463.
186. Pompili C, Detterbeck F, Papagiannopoulos K, et al. Multicenter international randomized comparison of objective and subjective outcomes between electronic and traditional chest drainage systems. *Ann Thorac Surg* 2014;98:490–497.
187. Cattaneo SM, Park BJ, Wilton AS, et al. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. *Ann Thorac Surg* 2008;85:231–236.
188. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. *Int J Radiat Oncol Biol Phys* 2003;57:875–890.
189. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004;58:1268–1279.
190. Grills IS, Hugo G, Kestin LL, et al. Image-guided radiotherapy via daily online cone-beam CT substantially reduces margin requirements for stereotactic lung radiotherapy. *Int J Radiat Oncol Biol Phys* 2008;70:1045–1056.
191. Keall P. 4-dimensional computed tomography imaging and treatment planning. *Semin Radiat Oncol* 2004;14:81–90.
192. Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDG-PET scans in various thoracic diseases. *Korean J Radiol* 2006;7:57–69.
193. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. *Cancer* 2011;117:4707–4713.
194. Oshiro Y, Mizumoto M, Okumura T, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. *J Thorac Oncol* 2012;7:370–375.
195. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys* 1991;21:109–122.
196. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010;76:S70–S76.
197. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol* 2006;24:4833–4839.
198. Borst GR, Ishikawa M, Nijkamp J, et al. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. *Int J Radiat Oncol Biol Phys* 2010;77:1596–1603.
199. Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. *Chest* 2012;141:858–866.
200. Barriger RB, Forquer JA, Brabham JC, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys* 2012;82:457–462.
201. Huang EX, Hope AJ, Lindsay PE, et al. Heart irradiation as a risk factor for radiation pneumonitis. *Acta Oncol* 2011;50:51–60.
202. Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? *Int J Radiat Oncol Biol Phys* 2005;61:64–69.
203. Bradley JD, Hope A, El Naga I, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. *Int J Radiat Oncol Biol Phys* 2007;69:985–992.
204. Palma DA, Senan S, Oberije C, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. *Int J Radiat Oncol Biol Phys* 2013;87:690–696.
205. Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. *Int J Radiat Oncol Biol Phys* 2004;58:213–219.
206. Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. *Int J Radiat Oncol Biol Phys* 2001;51:915–922.
207. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. *J Clin Oncol* 2005;23:2145–2154.
208. Ward WF, Molteni A, Kim YT, et al. Structure-function analysis of angiotensin-converting enzyme inhibitors as modifiers of radiation-induced pulmonary endothelial dysfunction in rats. *Br J Radiol* 1989;62:348–354.
209. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340:265–271.
210. O'Rourke N, Roque IFM, Farre Bernado N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. *Cochrane Database Syst Rev* 2010;(6):CD002140.
211. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. *J Clin Oncol* 2010;28:43–48.
212. Socinski MA, Stinchcombe TE, Moore DT, et al. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. *J Clin Oncol* 2012;30:3953–3959.
213. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;55:337–341.
214. Qiao WB, Zhao YH, Zhao YB, et al. Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. *World J Gastroenterol* 2005;11:2626–2629.
215. Gagliardi G, Constone LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. *Int J Radiat Oncol Biol Phys* 2010;76:S77–S85.
216. Schytte T, Hansen O, Stolberg-Rohr T, et al. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. *Acta Oncol* 2010;49:1058–1060.
217. King V, Constone LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1996;36:881–889.
218. Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. *J Clin Oncol* 2006;24:4100–4106.
219. Hooping MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst* 2007;99:365–375.
220. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. *J Clin Oncol* 2005;23:8597–8605.
221. Gianni L, Dombrowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. *Ann Oncol* 2001;12:1067–1073.
222. Chum M, Clough V, Slater A. Early onset of bilateral brachial plexopathy during mantle radiotherapy for Hodgkin's disease. *Clin Oncol (R Coll Radiol)* 2000;12:289–291.
223. Kong FM, Ritter T, Quint DJ, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. *Int J Radiat Oncol Biol Phys* 2011;81:1442–1457.
224. Eblan MJ, Corradetti MN, Lukens JN, et al. Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. *Int J Radiat Oncol Biol Phys* 2013;85:175–181.
225. The Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *Br Med J* 1995;311:899–909.
226. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. *Br J Cancer* 1995;71:366–370.
227. Thatcher N, Anderson H, Betticher DC, et al. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. *Anticancer Drugs* 1995;6:39–48.
228. Pignon J, Tribodet H, Scagliotti G, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. *J Clin Oncol* 2007;24:7008.

229. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–2139.
230. Johnson DH. Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go? *J Clin Oncol* 2014;32:1389–1391.
231. Sacher AG, Le LW, Leighl NB. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. *J Clin Oncol* 2014;32:1407–1411.
232. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. *Br J Cancer* 2012;106:1100–1106.
233. Djalalov S, Beca J, Hoch JS, et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. *J Clin Oncol* 2014;32:1012–1019.
234. Kelley MJ, McCrory DC. Prevention of lung cancer: summary of published evidence. *Chest* 2003;123:50S–59S.
235. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discov* 2011;1:44–53.
236. Wisniewsky J, Yung RC, Mathur PN, et al. Diagnosis and treatment of bronchial intraepithelial neoplasia and early lung cancer of the central airways: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e263S–e277S.
237. Detterbeck FC, Homer RJ. Approach to the ground-glass nodule. *Clin Chest Med* 2011;32:799–810.
238. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. *Radiology* 2013;266:304–317.
239. Yoshida J, Ishii G, Yokose T, et al. Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi Type B, in three patients. *J Thor Oncol* 2010;5:546–550.
240. Vest M, Herrin J, Soulos P, et al. Use of new treatment modalities for non-small cell lung cancer care in the Medicare population. *Chest* 2013;143:429–435.
241. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. *J Thorac Oncol* 2008;3:46–52.
242. Harpole DH Jr, Herndon JE II, Young WC Jr, et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. *Cancer* 1995;76:787–796.
243. Jones DR, Detterbeck FC. Surgery for stage I non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al., eds. *Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician*. Philadelphia, PA: W. B. Saunders; 2001:177–190.
244. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. *J Thorac Cardiovasc Surg* 1995;109:120–129.
245. Cangemi A, Volpino P, D'Andrea N, et al. Local and/or distant recurrences in T1-2/N0-1 non-small cell lung cancer. *Eur J Cardiothorac Surg* 1995;9:473–478.
246. Hubbard MO, Fu P, Margevicius S, et al. Five-year survival does not equal cure in non-small cell lung cancer: a surveillance, epidemiology, and end results-based analysis of variables affecting 10- to 18-year survival. *J Thorac Cardiovasc Surg* 2012;143:1307–1313.
247. Maeda R, Yoshida J, Hishida T, et al. Late recurrence of non-small cell lung cancer more than 5 years after complete resection: incidence and clinical implications in patient follow-up. *Chest* 2010;138:145–150.
248. West D, Rashid S, Dunning J. Does video-assisted thoracoscopic lobectomy produce equal cancer clearance compared to open lobectomy for non-small cell carcinoma of the lung? *Interact Cardiovasc Thorac Surg* 2007;6:110–116.
249. Whitson BA, Groth SS, Duval SJ, et al. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. *Ann Thorac Surg* 2008;86:2008–2018.
250. Phillips JD, Merkow RP, Sherman KL, et al. Factors affecting selection of operative approach and subsequent short-term outcomes after anatomic resection for lung cancer. *J Am Coll Surg* 2012;215:206–215.
251. Cooke D, Wisner D. Who performs complex noncardiac thoracic surgery in United States academic medical centers? *Ann Thorac Surg* 2012;94:1060–1064.
252. Boffa DJ, Kosinski A, Paul S, et al. Lymph node evaluation by open or video assisted approaches in 11,500 anatomic lung cancer resections. *Ann Thorac Surg* 2012;94:347–353.
253. Palade E, Passlick B, Osei-Agyemang T, et al. Video-assisted vs open mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a prospective randomized trial. *Eur J Cardiothorac Surg* 2013;44:244–249.
254. Petersen RP, Pham D, Burfeind WR, et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. *Ann Thorac Surg* 2007;83:1245–1250.
255. Jiang G, Yang F, Li X, et al. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer. *World J Surg Oncol* 2011;21:170.
256. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. *Ann Thorac Surg* 1995;60:615–622, discussion 623.
257. Lederle FA. Lobectomy versus limited resection in T1 N0 lung cancer (Letter). *Ann Thorac Surg* 1996;62:1249–1250.
258. Kim AW, Detterbeck F. Mediastinal lymph node dissection. In: Franco K, Thourani V, eds. *Cardiothoracic Surgery Review*. Philadelphia, PA: Lippincott Williams & Wilkins; 2012:1019–1022.
259. Darling GE, Allen MS, Decker PA, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial. *Chest* 2011;139:1124–1129.
260. Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer. *Ann Surg* 1998;227:138–144.
261. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. *World J Surg* 1998;22:290–294.
262. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. *Ann Thorac Surg* 2006;81:1013–1020.
263. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. *J Clin Oncol* 2010;28:35–42.
264. Scagliotti GV. The ALPI trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. *Clin Cancer Res* 2005;11:5011s–5016s.
265. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. *Eur J Cardiothorac Surg* 2004;26:173–182.
266. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. *J Clin Oncol* 2008;26:5043–5051.
267. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. *J Clin Oncol* 2005;23:4999.
268. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. *J Clin Oncol* 1996;14:1048–1054.
269. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systemic review and meta-analysis of individual patient data from nine randomised controlled trials. *Lancet* 1998;352:257–263.
270. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. *Radiother Oncol* 2002;62:11–19.
271. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. *J Clin Oncol* 2006;24:2998–3006.
272. Brunelli A, Kim AW, Berger K, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e166S–e190S.
273. Lau KK, Martin-Ucar AE, Nakas A, et al. Lung cancer surgery in the breathless patient—the benefits of avoiding the gold standard. *Eur J Cardiothorac Surg* 2010;38:6–13.
274. Brunelli A, Socci L, Refai M, et al. Quality of life before and after major lung resection for lung cancer: a prospective follow-up analysis. *Ann Thorac Surg* 2007;84:410–416.
275. Bobbio A, Chetta A, Carbone P, et al. Changes in pulmonary function test and cardio-pulmonary exercise capacity in COPD patients after lobar pulmonary resection. *Eur J Cardiothorac Surg* 2005;28:754–758.
276. Endoh H, Tanaka S, Yajima T, et al. Pulmonary function after pulmonary resection by posterior thoracotomy, anterior thoracotomy or video-assisted surgery. *Eur J Cardiothorac Surg* 2010;37:1209–1214.
277. Sielw W, Dango S, Kirschbaum A, et al. Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections. *Eur J Cardiothorac Surg* 2008;33:728–734.
278. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2008;72:967–971.
279. Rowe BP, Boffa DJ, Wilson LD, et al. Stereotactic body radiotherapy for central lung tumors. *J Thorac Oncol* 2012;7:1394–1399.
280. Nuytens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. *Radiother Oncol* 2012;102:383–387.
281. Palma DA, Senan S, Haasbeek CJ, et al. Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. *Int J Radiat Oncol Biol Phys* 2011;80:506–513.
282. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. *Lancet* 2010;375:1267–1277.

283. Martini N, Burt ME, Bains MS, et al. Survival after resection of stage II non-small cell lung cancer. *Ann Thorac Surg* 1992;54:460–466.
284. van Velzen E, Snijder RJ, de la Riviere AB, et al. Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. *Chest* 1996;110:1469–1473.
285. Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. *Ann Thorac Surg* 2005;80:268–275.
286. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. *Lung Cancer* 2002;36:1–6.
287. Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. *Ann Thorac Surg* 2003;76:1782–1788.
288. Ma Z, Dong A, Fan J, et al. Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis. *Eur J Cardiothorac Surg* 2007;32:20–28.
289. Douillard J, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. *J Thorac Oncol* 2010;5:220–228.
290. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. *J Clin Oncol* 2010;28:29–34.
291. Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. *Int J Radiat Oncol Biol Phys* 2008;72:695–701.
292. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. *J Clin Oncol* 2010;28:3138–3145.
293. American Joint Committee on Cancer. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2009.
294. International Union for Cancer Control. *TNM Classification of Malignant Tumors*. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009.
295. Kozower B, Lamer JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e369S–e399S.
296. Piehler JM, Pairolero PC, Weiland LH, et al. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. *Ann Thorac Surg* 1982;34:684–691.
297. Gould PM, Bonner JA, Sawyer TE, et al. Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 1999;45:91–95.
298. Patterson GA, Ilves R, Ginsberg RJ, et al. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. *Ann Thorac Surg* 1982;34:692–697.
299. Detterbeck FC, Socinski MA. IIB or not IIB: the current question in staging non-small cell lung cancer. *Chest* 1997;112:229–234.
300. Detterbeck FC, Kiser AC. T3 non-small cell lung cancer (stage IIb-IIIa). In: Detterbeck FC, Rivera MP, Socinski MA, et al., eds. *Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician*. Philadelphia, PA: W. B. Saunders; 2001:223–232.
301. Morgensztern D, Waqar S, Subramanian J, et al. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. *J Thorac Oncol* 2012;7:1479–1484.
302. Moreno A, Morgensztern D, Yu J, et al. Impact of preoperative radiation on survival of patients with T3N1>7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database. *J Surg Res* 2013;184:10–18.
303. Moreno A, Morgensztern D, Boffa D, et al. Treating stage IIIA-N1 disease: an analysis of very large, hilar lymph node positive non-small cell lung cancer using the National Cancer Data Base. *Ann Thorac Surg* 2014;97:1149–1155.
304. Detterbeck FC. Changes in the treatment of Pancoast tumors. *Ann Thorac Surg* 2003;75:1990–1997.
305. Foroulis CN, Zarogoulidis P, Darwiche K, et al. Superior sulcus (Pancoast) tumors: current evidence on diagnosis and radical treatment. *J Thorac Dis* 2013;5:S342–S358.
306. Anraku M, Waddell TK, de Perrot M, et al. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. *J Thorac Cardiovasc Surg* 2009;137:441–447.e1.
307. Bilsky MH, Vitaz TW, Boland PJ, et al. Surgical treatment of superior sulcus tumors with spinal and brachial plexus involvement. *J Neurosurg Spine* 2009;97:301–309.
308. Bolton WD, Rice DC, Goodyear A, et al. Superior sulcus tumors with vertebral body involvement: a multimodality approach. *J Thorac Cardiovasc Surg* 2009;137:1379–1387.
309. Fadel E, Missenard G, Chapelier A, et al. En bloc resection of non-small cell lung cancer invading the thoracic inlet and intervertebral foramina. *J Thorac Cardiovasc Surg* 2002;123:676–685.
310. Gandhi S, Walsh GL, Komaki R, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. *Ann Thorac Surg* 1999;68:1778–1785.
311. Grunenwald DH, Mazel C, Girard P, et al. Radical en bloc resection for lung cancer invading the spine. *J Thorac Cardiovasc Surg* 2002;123:271–279.
312. Muralidaran A, Detterbeck FC, Boffa DJ, et al. Long-term survival after lung resection for NSCLC with circulatory bypass: a systematic review. *J Thorac Cardiovasc Surg* 2011;142:1137–1142.
313. Kim AW, Detterbeck FC. Surgery for T4 and N3 non-small cell lung cancer, additional pulmonary nodules and isolated distant metastases. In: Kernstine K, Reckamp K, Thomas CJ, eds. *Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management*. New York, NY: Demos Medical Publishing; 2011:161–182.
314. Rendina EA, Venuta F, De Giacomo T, et al. Induction chemotherapy for T4 centrally located non-small cell lung cancer. *J Thorac Cardiovasc Surg* 1999;117:225–233.
315. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Clin Oncol* 2007;25:313–318.
316. Ramnath N, Dilling T, Harris L, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e314S–e340S.
317. Detterbeck F. What to do with surprise N2: intraoperative management of patients with non-small cell lung cancer. *J Thorac Oncol* 2008;3:289–302.
318. Detterbeck FC. N2 disease discovered at thoracotomy: resect or abort? In: Ferguson MK, ed. *Difficult Decisions in Thoracic Surgery: An Evidence-Based Approach*. 2nd ed. London, UK: Springer-Verlag; 2011:89–103.
319. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). *Lung Cancer* 2004;43:167–173.
320. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. *J Natl Cancer Inst* 2003;95:1453–1461.
321. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. *N Engl J Med* 2004;350:351–360.
322. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med* 2005;352:2589–2597.
323. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006;7:719–727.
324. Lally BE, Detterbeck FC, Geiger AM, et al. The risk of death from heart disease in patients with non-small cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. *Cancer* 2007;110:911–917.
325. Billiet C, Decaluwe H, Peeters S, et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. *Radiation Oncol* 2014;110:3–8.
326. Shen WY, Ji J, Zuo YS, et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial. *Radiation Oncol* 2014;110:120–125.
327. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. *Int J Radiat Oncol Biol Phys* 2005;61:318–328.
328. Feigenberg SJ, Hanlon AL, Langer C, et al. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. *J Thorac Oncol* 2007;2:287–292.
329. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group. *J Clin Oncol* 1988;6:9–17.
330. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. *J Clin Oncol* 2005;23:3270–3278.
331. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. *N Engl J Med* 2000;343:1217–1222.
332. Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected non-small cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). *Cancer* 1995;76:779–786.
333. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. *Ann Thorac Surg* 2008;86:912–920.
334. Burdett S, Stewart L, Ryzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. *Cochrane Database Syst Rev* 2007;(3):CD006157.

335. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. *J Clin Oncol* 2000;18:2981-2989.
336. Coughlin M, Deslauriers J, Beaulieu M, et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. *Ann Thorac Surg* 1985;40:556-560.
337. Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. *J Thorac Cardiovasc Surg* 1982;83:1-11.
338. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. *Lung Cancer* 1998;19:3-13.
339. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet* 2009;374:379-386.
340. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2): final report of RTOG 89-01. Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 2002;54:365-369.
341. Stephens R, Girling D, Hopwood P, et al. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer. *Lung Cancer* 2005;49:395-400.
342. Van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *J Natl Cancer Inst* 2007;99:442-450.
343. Kim AW, Faber LP, Warren WH, et al. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? *Ann Thorac Surg* 2009;88:937-944.
344. de Cabanyes Candela S, Dettnerbeck F. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. *J Thorac Oncol* 2010;5:389-398.
345. Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. *Lancet Oncol* 2008;9:636-648.
346. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-small-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. *Cancer* 1980;45:2744-2753.
347. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. *Int J Radiat Oncol Biol Phys* 2006;65:1075-1086.
348. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. *J Clin Oncol* 1990;8:1543-1555.
349. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. *Radiother Oncol* 1999;52:137-148.
350. Marino P, Pretoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. *Cancer* 1995;76:593-601.
351. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platinum compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. *Ann Oncol* 2006;17:473-483.
352. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011;103:1452-1460.
353. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 1999;17:2692-2699.
354. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. *J Clin Oncol* 2010;28:3739-3745.
355. Wang L, Wu S, Ou C, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. *Lung Cancer* 2012;77:89-96.
356. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. *J Clin Oncol* 2011;29:3120-3125.
357. Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. *J Natl Cancer Inst* 2010;102:859-865.
358. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. *J Clin Oncol* 2008;26:2450-2456.
359. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. *J Clin Oncol* 2008;26:5755-5760.
360. Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. *J Clin Oncol* 2007;25:1698-1704.
361. Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. *J Clin Oncol* 2010;28:2475-2480.
362. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2006;65:1106-1111.
363. Stinchcombe TE, Lee CB, Moore DT, et al. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. *J Thorac Oncol* 2008;3:1279-1285.
364. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. *J Clin Oncol* 2008;26:2457-2463.
365. Bradley JD, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617. *J Clin Oncol* 2013;31:Abstr 7501.
366. Schild SE, Stella PJ, Ceyer SM, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2002;54:370-378.
367. Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. *J Clin Oncol* 2005;23:3760-3767.
368. Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). *Eur J Cancer* 2007;43:114-121.
369. Cho KH, Ahn SJ, Pyo HR, et al. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. *Int J Radiat Oncol Biol Phys* 2009;74:1397-1404.
370. Arrieta O, Gallardo-Rincon D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. *J Thorac Oncol* 2009;4:845-852.
371. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. *J Clin Oncol* 2007;25:1698-1704.
372. Noonan K, Laskin J, Tong K, et al. Evaluation of a "Watch and Wait" approach for patients with newly diagnosed advanced NSCLC in a diverse community population. *J Thorac Oncol* 2013;8:Abstr 015.01.
373. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). *Chest* 2007;132:277S-289S.
374. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e341S-e368S.
375. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol* 2014;32:1277-1280.
376. Lilienbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol* 2005;23:190-196.
377. Ardizzone A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. *J Natl Cancer Inst* 2007;99:847-857.
378. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 2002;346:92-98.
379. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 2004;22:1589-1597.

380. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004;22:2184–2191.
381. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. *JAMA* 2004;292:470–484.
382. D'Addario G, Pintilie M, Leigh NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. *J Clin Oncol* 2005;23:2926–2936.
383. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. *Cancer* 2001;92:2639–2647.
384. Zukin M, Barrios CH, Rodrigues Pereira J, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. *J Clin Oncol* 2013;31:2849–2853.
385. Hikish TF, Smith IE, O'Brien ME, et al. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. *Br J Cancer* 1998;78:28–33.
386. Pallis AG, Gridelli C, van Meerbeek JP, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. *Ann Oncol* 2010;21:692–706.
387. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. *Lancet* 2011;378:1079–1088.
388. Hesketh PJ, Lilenbaum R, Chansky K, et al. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. *J Thor Oncol* 2007;2:494–498.
389. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. *AVAIL. J Clin Oncol* 2009;27:1227–1234.
390. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2013;31:4349–4357.
391. Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. *Lancet Oncol* 2010;11:733–740.
392. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet* 2009;373:1525–1531.
393. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. *J Clin Oncol* 2010;28:911–917.
394. Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. *Lancet Oncol* 2013;14:1326–1336.
395. Sequist LV, Yang J-C, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31:3327–3334.
396. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380–2388.
397. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121–128.
398. Zhou C, Wu Y, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) [abstract 7520]. *J Clin Oncol* 2012;30:30.
399. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239–246.
400. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385–2394.
401. Jänne PA, Wang X, Socinski MA, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. *J Clin Oncol* 2012;30:2063–2069.
402. Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. *Lancet Oncol* 2013;14:777–786.
403. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947–957.
404. Oxnard G, Arcila M, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. *Clin Cancer Res* 2011;17:5530–5537.
405. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
406. Chaff J, Oxnard G, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. *Clin Cancer Res* 2011;17:6298–6303.
407. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. *J Clin Oncol* 2002;20:1335–1343.
408. Smith IE, O'Brien MER, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. *J Clin Oncol* 2001;19:1336–1343.
409. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. *J Clin Oncol* 2007;25:5233–5239.
410. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2013;31:2895–2902.
411. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2012;30:3516–3524.
412. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. *Lancet* 2009;374:1432–1440.
413. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2010;11:521–529.
414. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol* 2009;27:591–598.
415. Edelman M, Le Chevalier T, Soria J. Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. *J Thor Oncol* 2012;7:1331–1336.
416. Beziak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J Clin Oncol* 2006;24:3831–3837.
417. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. *Lung Cancer* 2004;43:183–194.
418. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* 2000;18:2095–2103.
419. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353:123–132.
420. Ciuleanu T, Stelmakh L, Cician S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. *Lancet Oncol* 2012;13:300–308.
421. Kim E, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. *Lancet* 2008;372:1809–1818.
422. Garassino MC, Martelli O, Bettini A, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. *J Clin Oncol* 2012;30:Abstr LBA7501.
423. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci U S A* 2008;105:2070–2075.
424. Janne P, Ramalingam S, Yang J, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). *J Clin Oncol* 2014;32:Abstr 8009.
425. Yu H, Sima C, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. *J Thorac Oncol* 2013;8:346–351.
426. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. *J Clin Oncol* 2013;31:3987–3996.
427. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med* 2014;370:1189–1197.

428. Downey RJ, Ng KK, Kris MG, et al. A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. *Lung Cancer* 2002;38:193–197.
429. Cerfolio RJ, Bryant AS. Is palpation of the nonresected pulmonary lobe(s) required for patients with non-small cell lung cancer? A prospective study. *J Thorac Cardiovasc Surg* 2008;135:261–268.
430. Keogan MT, Tung KT, Kaplan DK, et al. The significance of pulmonary nodules detected on CT staging for lung cancer. *Clin Radiol* 1993;48:94–96.
431. Kunitoh H, Eguchi K, Yamada K, et al. Intrapulmonary subsesions detected before surgery in patients with lung cancer. *Cancer* 1992;70:1876–1879.
432. Port JL, Korst RJ, Lee PC, et al. Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? *Ann Thorac Surg* 2007;83:397–400.
433. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e455S–e497S.
434. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733–742.
435. Movsas B, Moughan J, Sama L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. *J Clin Oncol* 2009;27:5816–5822.
436. Perrin RG. Metastatic tumors of the axial spine. *Curr Opin Oncol* 1992;4:525–532.
437. Sundaresan N, Galicich JH, Lane JM, et al. Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization. *J Neurosurg* 1985;63:676–684.
438. Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. *Eur J Cancer* 1994;30a:22–27.
439. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet* 2005;366:643–648.
440. Gaspar LE, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. *Int J Radiat Oncol Biol Phys* 2000;47:1001–1006.
441. Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. *Int J Radiat Oncol Biol Phys* 2012;82:2111–2117.
442. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. *Am J Roentgenol Radium Ther Nucl Med* 1971;111:334–336.
443. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494–500.
444. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. *JAMA* 1998;280:1485–1489.
445. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet* 2004;363:1665–1672.
446. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol* 2009;10:1037–1044.
447. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. *Pract Radiat Oncol* 2012;2:210–225.
448. Wilson LD, Dettterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med* 2007;356:1862–1869.
449. Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruction. Is it a medical emergency? *Am J Med* 1981;70:1169–1174.
450. Yu JB, Wilson LD, Dettterbeck FC. Superior vena cava syndrome—a proposed classification system and algorithm for management. *J Thorac Oncol* 2008;3:811–814.
451. Martins SJ, Pereira JR. Clinical factors and prognosis in non-small cell lung cancer. *Am J Clin Oncol* 1999;22:453–457.